Sai Life Sciences Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 27,710,560 (50%) | — | ₹152,131 Cr |
| NII (HNI) | — | 8,313,169 (15%) | — | ₹45,639 Cr |
| Retail | — | 19,397,394 (35%) | — | ₹106,492 Cr |
| Σ Total | — | 55,421,123 (100%) | — | ₹3,042,620 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 27 | ₹14,823 |
| Retail (Max) | 13 | 351 | ₹192,699 |
| S-HNI (Min) | 14 | 378 | ₹207,522 |
| B-HNI (Min) | 67 | 1,809 | ₹993,141 |
Financial Statements Amount in Crore
| Metric | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Revenue | 693 | 1,494 | 1,245 |
| Profit After Tax | 28 | 83 | 10 |
| Net Worth | 1,045 | 974 | 887 |
| Total Assets | 2,477 | 2,275 | 2,187 |
| Reserves & Surplus | 1,025 | 954 | 867 |
| Total Borrowing | 764 | 710 | 699 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- Repayment/prepayment in full or part, of all or certain outstanding borrowings availed by the Company and –
- General corporate purposes –
Company Overview
Incorporated in January 1999, Sai Life Sciences Limited researches, develops, and manufactures small-molecule new chemical entities. The company offers tailor-made services to biotech firms and global pharma companies.
In the Financial Year 2024 and for the month ending September 30, 2024, the company provided services to over 280 innovator pharmaceutical companies, including more than 230 in that month alone. Among these clients, the company worked with 18 of the top 25 pharmaceutical companies based on their revenue in the calendar year 2023.The services were offered across countries such as the US, the UK, Europe, and Japan.
The company's business development team consists of 16 experienced and qualified professionals, with six located in the US, nine in the UK and Europe, and one in Japan.
The company has the following service offerings.
- Capabilities in chemistry, manufacturing, and control(“CMC”)/contract development and manufacturing organisations (“CDMO”).
- CRO services include integrated discovery (“Discovery”) capabilities across biology, chemistry, drug metabolism and pharmacokinetics
As of September 30, 2024, the company had 2,353 scientific staff, with the majority of the scientific team holding advanced degrees, including 302 Ph. D.s and 1,475 master’s degrees.
As of September 30, 2024, the company had 3135 employees with capabilities across the CRDMO value chain.
Competitive Strength:
- As an integrated CRDMO, the company provide a complete platform for discovery, development, and manufacturing.
- CRO services include integrated discovery capabilities across biology, chemistry, and drug metabolism and pharmacokinetics.
- CDMO platform with a diverse mix of commercial and under-development molecules